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Oxidative stressurbances occur in response to the consumption of a high fat western diet. Such
metabolic disturbances can include the progressive development of hyperglycemia, hyperinsulemia, obesity,
metabolic syndrome, and diabetes. Cumulatively, diet-induced disturbances in metabolism are known to
promote increased morbidity and negatively impact life expectancy through a variety of mechanisms. While
the impact of metabolic disturbances on the hepatic, endocrine, and cardiovascular systems is well
established there remains a noticeable void in understanding the basis by which the central nervous system
(CNS) becomes altered in response to diet-induced metabolic dysfunction. In particular, it remains to be fully
elucidated which established features of diet-induced pathogenesis (observed in non-CNS tissues) are
recapitulated in the brain, and identiﬁcation as to whether the observed changes in the brain are a direct or
indirect effect of peripheral metabolic disturbances. This review will focus on each of these key issues and
identify some critical experimental questions which remain to be elucidated experimentally, as well as
provide an outline of our current understanding for how diet-induced alterations in metabolism may impact
the brain during aging and age-related diseases of the nervous system.
© 2008 Published by Elsevier B.V.1. Western diet, metabolic dysfunction, and metabolic syndrome
In the last decade there has been a tremendous shift in both the
composition of the daily diet as well as the basic dietary habits of
Western societies, whereby a growing percentage of the population
primarily consumes a diet that is high in fat, and a diet whereby an
excess of calories is consumed on a regular basis. Studies as early as
1913 highlighted the relationship between the consumption of a high
fat diet and the development of hyperglycemia [1], demonstrating
that a high fat diet is sufﬁcient to promote systemic metabolic
disturbances. Similarly, studies have established that overfeeding or
excessive caloric intake is sufﬁcient to promote systematic metabolic
disturbances in both rodents and humans [2–5]. As such it is now clear
that there is a tremendous and negative impact on metabolic balance
in a growing percentage of individuals in Western society as the result
of both increased dietary fat and elevated caloric intake. This dietary-
mediated increase in metabolic dysfunction is evident in the
manifestation of the growing percentage of individuals who exhibit
hyperglycemia, hyperinsulemia, insulin resistance, dyslipidemia,
triglyceremia, and free fatty acid disturbances. Cumulatively, these
aspects of metabolic dysfunctionwill undoubtedly increase morbidity
and mortality in Western societies in an unprecedented manner.
The focus of this review is to provide a comprehensive and focused
analysis of how dietary-induced metabolic dysfunction is capable of
disrupting brain homeostasis and likely contributes to the develop-lsevier B.V.ment of brain dysfunction and brain pathogenesis. In particular this
review will discuss the potential interplay between diet-induced
alterations in metabolism and the resulting changes in the brain
homeostasis which occur during aging and age-related diseases of the
nervous system.
Before moving on to a discussion of the interplay between
metabolic dysfunction and brain pathogenesis it is worth spending a
moment to clarify the progressive nature by which a high fat western
diet promotes systematic metabolic disturbances. This is because
most of the current literature on the brain and metabolic dysfunction
have focused solely on the effects of diabetes, which is one of the last
and most devastating forms of metabolic dysfunction that can be
induced by a western diet. Certainly diabetes is capable of promoting
brain disturbances, however in addition to the irreversible state of
diabetes, one must also consider the impact a pre-diabetic state may
have on brain homeostasis. Currently there are believed to be 41
million Americans that can be considered to be prediabetic, with the
prediabetic state is associated with a progressive development of
multiple metabolic disturbances which precedes the irreversible stage
of diabetes, and importantly can even occur independent of the
development of diabetes [2–8]. The speciﬁc clinical endpoints that are
most commonly utilized to identify prediabetic individuals include
the presence of an impaired fasting glucose (IFG) and an impaired
glucose tolerance (IGT) test. Biochemically, these diet-induced
disturbances in metabolism commonly occur in a progressive and
somewhat systematic manner (Fig 1). One of the earliest metabolic
disturbances which is known to occur in the development of dietary
induced diabetes is an increase in the ﬂux of free fatty acids (FFA) into
Fig. 1. Progression from euglycemic state to diabetes. In contrast to the a healthy
euglycemic state, the consumption of a western diet is sufﬁcient to increase the
dysfunction of a number of aspects of metabolism. The temporal proﬁle by which many
on these metabolic disturbances occur is provided to allow for identiﬁcation of early
and late events in the progression to diabetes. HDL: high density lipoprotein; BMI: body
mass index.
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followed by the deposition of triglycerides into these same tissues (Fig
1). Elevations in FFA are believed to promote metabolic disturbances
in part by impairing the ability of cells to store glucose and to respond
to insulin, which cumulatively (according to the Randle hypothesis)
are capable of promoting the development of diabetes. Accompanying
each of these alterations there is observed to be an elevation in
circulating levels of cytokines, altered levels of speciﬁc adipose
derived factors (termed adipokines), and further sustained elevations
in FFA levels (Fig 1). Cumulatively, these events lead to elevated levels
circulating insulin (hyperinsulemia), whereby the body attempts to
overcome the impairment of downstream insulin signaling by
sustaining higher and higher levels of circulating insulin (Fig 1).
Allowed to persist these conditions give rise to continually elevated
levels of glucose (due to impaired insulin-mediated regulation of
glucose levels) and can promote pancreatic beta cell damage to the
point that an irreversible state of metabolic dysfunction occurs (i.e. -
diabetes) (Fig 1).
In addition to the identiﬁcation of a pre-diabetic state, studies have
now established a clinical phenotype referred to as metabolic
syndrome [9–11]. Metabolic syndrome is clinically deﬁned by the
presence of up to 5 different cardiovascular risk factors. These factors
are the presence of abdominal obesity, low HDL, hypertension,
hyperglycemia, and hypertriglyceridemia. While the identiﬁcation of
metabolic syndrome as a clinical entity is largely accepted, some
debate remains as to the threshold that must be reached for each of
these factors to achieve a diagnosis of metabolic syndrome. For
example National Education Program Third Adult Treatment Panel
Guide (NCEP) requires that patients meet at least 3 of the following
criteria: abdominal obesity (waist circumference of N88 cm for
women and greater than 102 cm for men), hypertriglycermia (greater
than 150 mg/dL), low HDL cholesterol (less than 40 mg/dL for men
and less than 50 mg/dL for women), high blood pressure (systolic
greater than 130 mm Hg, diastolic greater than 85 mm Hg), high
fasting glucose (greater than 110 mg/dL). Again, it is important to
point out that metabolic syndrome is a pre-diabetic state, which
identiﬁes that deleterious changes in metabolism can occur indepen-
dent of the existence of diabetes (Fig 1). While understanding the
effects of diabetes on the brain is important, and has received the
largest amount of attention to date, it is equally important to
understand the effects of the pre-diabetic state and presence of
metabolic syndrome on brain homeostasis. This is based on the fact
that a signiﬁcant percentage of individuals will not progress to
diabetes, and will potentially exist in a pre-diabetic state for decades.
Additionally, understanding the earliest alterations in brain home-
ostasis that occur following metabolic dysfunction (non-diabetes or
pre-diabetes), may allow for understanding how speciﬁc metabolic
disturbances contribute to the more advanced and pathogenic
alterations in brain homeostasis.2. Metabolic dysfunction and effects on brain physiology
As part of normal brain function the brain is required to acquire,
process, store, and retrieve large amounts of information. Each of
these functions can be placed into different functional categories
including working memory (short term), implicit memory (task
associated), and declarative memory (recall of facts and events). As
the result of a variety of stressors the function and performance of the
brain can become impaired and ultimately result in dementia.
Considerable clinical evidence suggests that a western diet, and the
presence of metabolic dysfunction (pre-diabetic or metabolic syn-
drome), are sufﬁcient to promote the development of cognitive
disturbances and even dementia. For example, three separate studies
(Health Aging and Body Composition Study, Sacramento Area Latino
Study of Aging (SALSA), Longitudinal Aging Study Amsterdam) have
demonstrated a signiﬁcant and inverse correlation between the
presence of metabolic syndrome and a longitudinal decline in
cognitive performance [12–16]. Importantly, cognitive decline in
these studies was determined using a number of established cognitive
assessments including the mini mental status exam, delayed word-list
recall, and coding tasks. Additionally, one recent longitudinal study
demonstrated that obesity increased the risk for dementia (74%), even
after adjusting for diabetes and cardiovascular disease [17]. Similarly
studies identiﬁed that abdominal adipocity in the elderly increased
the incidence of dementia even after correcting for age [18]. Also, non-
elderly obese individuals have been demonstrated to have more
severe brain atrophy as compared to non-obese individuals of the
same age [19]. Together, these data clearly link diet-inducedmetabolic
disturbances to the development of a number of cognitive distur-
bances and dementia.
A critical feature of the aforementioned clinical studies is that they
each also identiﬁed that the cognitive decline in aged individuals with
metabolic syndrome were much more affected than non-aged
individuals, and that in every study there was a signiﬁcant and
inverse correlation between the level of cognitive performance and
the presence of peripheral indices of inﬂammation. These inﬂamma-
tory markers included elevated circulating levels of C-reactive
peptide, alpha-1-antichymotrypsin, and interleukin-6. Although
each of these previously mentioned studies examined the relationship
between cognition in non-diabetics, data from the Framingham study
has also demonstrated a link between type 2 diabetes and lower
cognition scores [20].
The aforementioned data from population and epidemiological
based studies are further supported from a number of rodent studies
that link diet-induced metabolic dysfunction to the development of
cognitive abnormalities. For example diet induced obesity in rodents
is sufﬁcient to promote cognitive disturbances in aging and young
rodents [21–25]. Interestingly, rodent studies have demonstrated a
potential role for glucocorticoids, hypertriglyceridemia, and oxidative
stress in promoting brain disturbances in some rodent models of
obesity [26].
It is important to point out that the majority of studies on aging
and dietary effects on the brain have centered on understanding how
long term type 2 diabetes mellitus inﬂuences brain function.
Additionally, rodent studies have primarily focused on taking young
rodents and placing them on long term diets, and maintaining them
on such diets whereby animals age with the long term complications
associated from having diabetes. These studies, while informative, do
not provide important insight as to how a long term and persistent
state of pre-diabetes or metabolic syndrome affect brain homeostasis.
Additionally, previous studies are not generally designed to under-
stand how aging may inﬂuence the ability of a western diet, and/or
the presence of prediabetic state/metabolic syndrome state, to
promote brain disturbances. Based on epidemiological studies and
experimental evidence in rodents it is highly likely that independent
of diabetes, the presence of western diet-induced metabolic
Fig. 2. Diet-induced increases in brain dysfunction and brain pathology. Consumption of a western diet is sufﬁcient to promote metabolic dysfunction that can then lead to the
development of brain pathology and cognitive disturbances. Aging likely promotes the ability of awestern diet to promotemetabolic dysfunction, and deleterious effects on the brain,
while several clinically relevant interventions (western diet cessation, antioxidants, anti-inﬂammatory, anti-diabetics) likely ameliorate the effects of a western diet on metabolism
and the brain.
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neuropathology that can be considered a form of accelerated aging
(Fig 2). It is important to point out that there remains a tremendous
void in our understanding as to which neurochemical and/or
neuropathological criteria are responsible for mediating the afore-
mentioned described disturbances in cognition (see below). It is likely
that aging itself is sufﬁcient to further accelerate the effects of a
western diet and diet-inducedmetabolic dysfunction on the brain (Fig
2). Together, these concepts have important implications for under-
standing what neurological disturbances are expected to occur within
the large swath of the population regularly consuming a high fat
western diet in the United States.
3. Metabolic dysfunction and effects on brain pathology
It is presumed that brain pathology serves as a substrate for
declines in brain performance and ultimately to the development of
dementia. However, the mechanism(s) by which pathology contri-
butes to cognitive disturbances is not linear and is clearly complex
[27,28], likely relying on not only the amount of overall pathology but
also taking into account the ability of the brain to adapt or respond to
the presence of pathology. Regardless, a number of pathologies occur
as part of normal brain aging and age-related diseases of the brain
[27,28]. Key age-related pathologies include the development of
proteinateous aggregates/inclusions (neuroﬁbrillary tangles, Lewy
Bodies, lipofuscin ceroid, extracellular beta amyloid deposits) and
neurochemical alterations (altered trophic factor support, oxidative
stress, mitochondrial abnormalities). In addition to these manifesta-
tions studies have identiﬁed a number of vascular abnormalities
which appear to be pathological features of brain aging and age-
related diseases of the nervous system. The potential for each of these
factors contributing to cognitive disturbances following consumption
of a western diet is discussed in more detail below.
3.1. Metabolic disturbances and the development of protein aggregates
While some studies have demonstrated a link between the
presence of diabetes, and the presence of cognitive deterioration
and neuropathology, several controversial aspects remain to beelucidated. For example, most neuropathological studies in humans
have demonstrated that there is no positive correlation between the
presence of diabetes and the presence of AD related pathology [28,29].
Such a discrepancy may arise as the result of the exclusion criteria
used in these and other neuropathological studies, as well as the fact
that most studies do not take into account the duration or severity of
diabetes in the subjects analyzed. Surprisingly, at the present time
there appears to be no current publications demonstrating the ability
of pre-diabetic state or metabolic syndrome to modulate AD related
pathology. However, it is again worth noting that studies have
demonstrated a link between metabolic syndrome and the clinical
diagnosis of AD dementia [30]. Studies examining the pathology in
prediabetic individuals and individuals with metabolic syndrome are
essential to begin to understand the reciprocal relationship between
diet-induced metabolic dysfunction and the promotion of brain
pathogenesis. On a similar note, there is nothing known with regard
to the ability of a pre-diabetic state to modulate the presence of
several well established protein-based pathologies in the brain such as
neuroﬁbrillary tangles, Lewy bodies, or lipofuscin-ceroid. Rodent
studies have demonstrated the ability of a high fat and high-sucrose
diet to promote the development of extracellular beta amyloid
deposits [28,29,31–34], although as stated above, there does not
appear to be a strong body of evidence supporting the ability of
diabetes or diet-inducedmetabolic dysfunction to increase the burden
of beta amyloid deposition in the human brain.
Given the large amount of studies in both rodents and humans that
demonstrate the ability of diet-induced metabolic dysfunction to
promote cognitive disturbances and dementia [30,35–40], with a
corresponding lack of studies showing increased levels of neuro-
pathology in the brain, these data raise the possibility that diet-
induced cognitive disturbances are not mediated by some of the most
established and well characterized forms of protein/peptide-based
pathologies (beta amyloid deposition, neuroﬁbrillary tangles, Lewy
bodies, lipofuscin-ceroid). Additionally, such data may highlight the
potential for other neurochemical and neuropathological features
potentially serving as mediators of diet-induced cognitive distur-
bances. Below we discuss the potential for altered trophic factor
support, mitochondrial abnormalities, and/or oxidative stress serving
as key mediators of diet-induced disturbances of the brain.
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support
A growing body of literature has demonstrated the ability of a high
fat diet and diabetes to alter the level of trophic factors [41–45]. In
particular both diabetes and high fat diets have been demonstrated to
alter the level of essential trophic factors such as brain derived
neurotrophic factor (BDNF), raising the possibility of high-fat diets
promoting brain disturbances via altering the levels of neuroprotec-
tive molecules such as BDNF [41–45]. Such changes in neurotrophic
factor signaling would be expected to promote deleterious changes in
signal transduction pathways, given that neurotrophic factors pro-
mote MAPK and CREB signaling, which are both necessary for
neuronal homeostasis [41–44]. It is interesting to also note the strong
link between decreased circulating levels of neurotrophic factors and
depression [43], with metabolic dysfunction potentially contributing
to depression in aging and age-related diseases via altering the
circulating levels of key trophic factors [43].
3.3. Metabolic disturbances and development of mitochondrial
abnormalities
Diet-induced metabolic disturbances, independent of diabetes, are
associated with decreased expression of genes involved in oxidative
phosphorylation and decreased expression of genes involved in
mitochondria biogenesis [46–48]. These studies are coupled to
additional reports demonstrating that reduced mitochondrial biogen-
esis occurs in response to a high fat diet as well as during diabetes
[49–51]. In addition to producing fewer mitochondria via reduced
biogenesis, studies have reported on the ability of high-fat diet
consumption to decrease the levels of complex 1 activity within
mitochondria [46]. Together, these data demonstrate the ability of
high-fat western diets to rapidly promote pronounced effects on the
function of mitochondria, with efﬁcient mitochondrial function
essential to brain homeostasis. A central focus of much brain aging
and age-related neurodegeneration research is centered on under-
standing and preventing deleterious changes in mitochondrial home-
ostasis within the brain [28,52,53]. At present it is unclear if brain
mitochondria respond similarly as muscle or liver mitochondria, in
response to consumption of a high-fat western diet. If brain
mitochondria, particularly mitochondria within the synapse, undergo
altered biogenesis and function in response to a western diet it would
open the door for novel mechanisms by which peripheral metabolic
disturbances promote deleterious changes in themetabolic capacity of
the brain.
Decreased levels of mitochondrial biogenesis and mitochondrial
function promote an increase in fatty acid oxidation, as an alternative
source for ATP generation [46,47]. However, long term upregulation of
fatty oxidation in tissues such as the muscle or liver (and likely the
brain), would be expected to have adverse effects on cellular
homeostasis. Such deleterious outcomes from chronic elevations in
fatty oxidation include elevated levels of oxidative stress and
ultimately insufﬁcient genesis of ATP. Again, it is important to note
that our understanding of western diet-induced effects mitochondrial
abnormalities have centered on non-CNS tissues, butmay also occur in
tissues such as the brain, and thus may have important implications
for the development of dysfunction and pathology of the brain.
3.4. Metabolic dysfunction and increased oxidative stress
Recent studies indicate that oxidative stress may be the earliest
step inwestern diet-induced pathogenesis [54], andmay be one of the
earliest and most important steps in the development of insulin
resistance. Oxidative stress occurs when oxidative modiﬁcations to
different cellular components causes cells to undergo deleterious
changes in homeostasis due to an inability to repair or replace themacromolecules possessing oxidative damage, or as the result of
insufﬁcient synthesis of protective macromolecules to counteract the
deleterious effects of oxidative damage [55–57]. Reactive oxygen
species (ROS) are formed as the byproduct of many physiological
processes, and can arise from both enzymatic as well as non-
enzymatic sources. Well established ROS include superoxide anion,
hydroxyl radical, singlet oxygen, and hydrogen peroxide. Each of these
ROS is extremely unstable (and therefore reactive) due to the fact they
contain an unpaired electron which causes them to rapidly interact
with proteins, nucleic acids, and lipids.
There are many modes of protein oxidation which include metal
catalyzed oxidation, amino acid oxidation, oxidation induced cleavage,
and the conjugation of lipid oxidation products [55]. ROS mediated
cleavage of peptide bonds occurs principally via the diamide pathway
and the alpha-amidation pathway. Both cysteine and methionine
residues can interact with ROS resulting in the production of sulfoxide,
sulfenic acids, and disulﬁde bridges. By far the most characterized and
studied oxidative modiﬁcation to proteins is the protein carbonyl. The
most well studies lipid oxidation-protein conjugate are the adducts
mediated by the lipid peroxidation product (4-hydroxynonenal).
In addition to the oxidation of proteins, lipid peroxidation can
contribute to the development of oxidative stress. A wide variety of
lipid peroxidation products have been identiﬁed and demonstrated to
mediate varying degrees of toxicity in the brain and other tissues [58].
The best characterized of the lipid peroxidation products is 4-
hydroxynonenal (HNE) which is capable of altering cellular home-
ostasis via the aforementioned adduct formation and protein cross-
linking [58]. Studies have identiﬁed a role for HNE and other lipid
peroxidation in normal brain aging as well as a variety of age-related
neurodegenerative disorders [58–63]. Lastly, the oxidation of nucleic
acids is capable of promoting oxidative stress in a variety of tissues
including the brain [28,57–61]. Oxidation of DNA is the best
characterized but studies have also identiﬁed that oxidation of RNA
may serve as a more sensitive marker of oxidative stress in the brain.
Increased levels of oxidative stress are evident in experimental
models of western diet-induced metabolic dysfunction as well as
samples from humans with diet-induced metabolic dysfunction
[2,15,54,61,64–68]. For example studies of tissues following western
diet consumption have demonstrated evidence for increased levels of
oxidative damage to nucleic acids, proteins, and lipids [54,64–68].
Taken together, these data suggest that the dysfunction of tissues
following western diet consumptionmay be due to the adverse effects
of oxidative stress.
While there is signiﬁcant evidence for oxidative stress potentially
contributing to the pathogenesis associated with western diet
consumption, several critical issues remain to be experimentally
elucidated. For example, at present it remains unclear as to which cell
types and brain regions are most vulnerable to the deleterious effects
of western diet-induced oxidative stress. Additionally, it is unclear
whether aging potentially exacerbates the ability of a western diet to
induce oxidative stress in these same cell types and brain regions.
Deﬁning these aspects of western diet-mediated changes in brain
homeostasis will allow us to begin to critically understand how the
brain is affected by western diet consumption. Similarly, under-
standing the relative susceptibility of the cerebral cortex and
hippocampus to undergo elevations in oxidative stress, relative to
the hypothalamus, will have important implications for understand-
ing the potential contribution of western diet-induced oxidative stress
to subsequent neurobehavioral disturbances. Lastly, studies are
needed to deﬁne which forms of oxidative stress (protein, lipid,
nucleic acid oxidation) are most important to the development of
western diet-induced disturbances in cognition. When such data is
available investigators will be able to deﬁne themolecular and cellular
basis by which oxidative stress potentially contributes to brain
dysfunction in the adult and aged brain. Such data have tremendous
implications for not only normal brain aging, but also understanding
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contribute to the development of a wide variety of age-related
dementias including AD.
4. Future areas of research
As pointed out above, we currently know very little with regard to
exactly how dietary factors (such as a high fat western diet) modulate
brain homeostasis during the agingof the brain. It is clear that there are
clinical and rodent studies which strongly link diet-inducedmetabolic
disturbances (in absence of diabetes) to the development of dementia.
The progressive nature by which western diet consumption promotes
brain disturbances raises the possibility that by studying thismodelwe
will be better able to not only understand the linkages between
metabolism and the brain, but also begin to understand the complex
relationship between brain pathology and altered brain function.
It remains unclear as to which peripheral pathologies that are
associated with a western diet, are also observed in the brain.
Identifying the similarities and temporal proﬁles of these brain
changes, as related to peripheral tissues, may allow for mechanistic
insight as to howhigh fat western diets disrupt brain homeostasis. One
key aspect to investigate in the future will be to elucidate whether
western diet consumption potentially mediates brain disturbances via
reducing the ability of the brain to successfully respond to stressors (as
is observed in other tissues). A decreased capacity to repair or replace
damaged brain systems may play a causal role in promoting both
neuropathology and neurobehavioral deﬁcits. For example, decreased
trophic support or vascular support in response to a western diet (as
reported in non-CNS tissues) would be expected to potentially
contribute to the development of neuropathology and dementia.
In speculating for this portion of the manuscript the authors are
particularly excited about the potential that we might be able to gain
mechanistic insight to the “sundowning” which is observed in the
elderly and individuals with dementia. “Sundowning” occurs when
there is increased confusion and cognitive disturbances in these
individuals in later stages of the day [69]. While most studies have
focused on the potential contribution of fatigue, low lighting, and
changes in home environment as triggers to sundowning one can also
envision a role for metabolic disturbances contributing to sundown-
ing. Metabolic disturbances, which likely can be successfully modu-
lated using pharmaceutical or nutritional interventions, may play a
key role in reducing or delaying sundowning. Additionally, sundown-
ing may be another key experimental model for understanding how
pathology (aging, age-related neurodegenerative conditions) contri-
bute to subsequent cognitive disturbances. Increasing the amount of
“good days”, or high level of cognitive function within a given day in
demented individuals, will likely be a key area to target with future
dementia research.
The ﬁndings discussed in this review have demonstrated a role for
diet-induced disturbances in metabolism (in the absence of diabetes)
to serve as mediators of neuropathology and dementia. These data
highlight the potential for using diet-based studies as a means of
understanding the relationship between pathology and dementia, and
the reciprocal relationship of individual pathologies and neurochem-
ical disturbances to one another. The fact that in the pre-diabetic state
the effects of a western diet are partially or even fully reversible raises
a tremendous opportunity for the development of potential ther-
apeutic interventions. Such therapies may be either behavioral
(cessation of western diet and increased exercise), or pharmacological
based (Fig 2), and considerable research is needed to understand the
efﬁcacy of such interventions towards western diet-induced effects on
the brain.
Certainly the concept of linking diet-induced metabolic dysfunc-
tion to brain pathogenesis and dementia is not a new concept, for
example in 1996 Smith et al postulated a linking between diabetes and
Alzheimer's disease based on the common link of increased levels ofadvanced glycation end products (AGE) in each of these disorders
[70]. Additionally, work from the Smith and Perry group went on to
outline the ability of AGE to mediate many aspects of Alzheimer's
disease pathogenesis [71,72], suggesting an active role for AGE's in
Alzheimer's. What this review focuses on is the novel concept that a
pre-diabetic state (independent of diabetes) is likely sufﬁcient to
accelerate many aspects of brain aging including increased levels of
dementia and brain pathogenesis. This has important implications for
the 71 million pre-diabetic individuals in the United States who are all
aging, and a vast majority of which will never go on to develop
diabetes. We propose that these individuals will likely have an
increased propensity for age-related dementia's, andwill likely exhibit
accelerated brain aging on both a pathological as well and neurophy-
siological level. Understanding the effects of a pre-diabetic on the
aging brain, and understanding what effects can be reversed by
routinely prescribed interventions is a critical area of future research.
Taken together, these ﬁnding highlight the importance of continuing
research on this exciting area of research, which has not only
tremendous implications for our understanding of the brain and the
genesis of brain disease, but also for our understanding of how the
daily choices in our diet lays the groundwork for the development or
prevention of brain disease.
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